 The European Medicines Agency approved it for the treatment of PNH in June 2007, and in November 2011 for the treatment of aHUS.Health Canada approved it in 2009 to treat PNH and in 2013 as the only drug to treat aHUS.Eculizumab was approved by the FDA for AQP4+ NMO in 2019, based on the results of the PREVENT trial.